ArticleJournal of neurodevelopmental disorders2026
Phenotyping iPSC-derived neurons from Angelman patients and partial rescue via JNK pathway inactivation.
Article in Journal of neurodevelopmental disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAngelman Syndrome (AS, MIM #105,830) is a rare neurodevelopmental disorder caused by imprinting defects, and it is marked by motor impairment, intellectual disability, speech limitations, and seizures. The condition arises due to the loss of function in neurons of the maternally-inherited UBE3A gene, mapping in the imprinted chromosomal region 15q11.2-q13, through a variety of genetic and epigenetic mechanisms. UBE3A encodes a ubiquitin E3 ligase, which is essential for synaptic plasticity. Most studies of AS have been performed on animal models, while induced pluripotent stem cells (IPSCs), mainly generated from patients with deletion, remain limited in number.
methodsHere we report on the generation and characterization of human cortical neurons derived from IPSCs obtained from children representative of the main AS genotypes: 3 with 15q11-13 deletion, 3 with UBE3A mutations, 3 with uniparental disomy, and 2 with imprinting defects.
resultsDuring early neuronal differentiation, morphological analyses highlighted a reduced dendritic branching and an increased number of thin filopodia, while migration assays revealed reduced neurite mobility in AS human neurons with the most severe genetic defect, namely the 15q11-13 deletion. At a later differentiation time point, electrophysiological analyses revealed impaired neuronal activity in AS patient-derived neurons. To investigate pathways potentially involved in synaptic dysfunction, we examined the JNK (c-Jun N-terminal kinase) signalling pathway, which plays key roles in neuroinflammation and synaptic development. We found increased JNK activation and, importantly, treatment with a JNK-inhibitor, D-JNKI1, partially rescued the neuronal morphological defects, significantly reducing the number of immature protrusions, as well as defects in electrophysiological properties.
conclusionsOur patient-specific models contribute elucidate how loss of UBE3A leads to aberrant neuronal maturation and function in the precocious stages of neuronal development and how treatment with D-JNKI1 may pave the way for new therapeutic possibilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.